Gene
PRKCH
PRKCH is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (5), Actionable biomarkers (2), Target-disease associations (292), and 4 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
5 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the papers our biomarker dictionary matched in a year mention PRKCH. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
PRKCH has 7 publication mentions across 6 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Publication mentions | Share of that year |
|---|---|---|
| 2023 | 0 of 11,460 | 0.00% |
| 2022 | 0 of 13,598 | 0.00% |
| 2021 | 0 of 15,045 | 0.00% |
| 2020 | 1 of 14,459 | 0.01% |
| 2019 | 0 of 12,159 | 0.00% |
| 2018 | 1 of 11,854 | 0.01% |
| 2017 | 0 of 11,595 | 0.00% |
| 2016 | 1 of 10,983 | 0.01% |
| 2015 | 0 of 11,395 | 0.00% |
| 2014 | 1 of 10,367 | 0.01% |
Showing 10 of 34 years.
Assay-provider ledger (5)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| NanoString Technologies | Unclassified | Clinical validation | 1 | June 18, 2019 |
| Agilent Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | July 25, 2017 |
| Fluidigm | Reagent supplier | Clinical validationAnalytical validation | 1 | July 25, 2017 |
| Invitrogen | Reagent supplier | Clinical validationAnalytical validation | 1 | July 25, 2017 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 1 | July 25, 2017 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| PRKCH amplification + ABL1-BCR fusion | Imatinib | response-associated | chronic myelogenous leukemia | Cancer Genome Interpreter |
| PRKCH amplification + ABL1-BCR fusion | Trametinib | response-associated | chronic myelogenous leukemia | Cancer Genome Interpreter |
Target-disease associations (292)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| Aicardi-Goutieres syndrome 2 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Aicardi-Goutières syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Alymphoid cystic thymic dysgenesis | immune system disease | Mouse knockout (IMPC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 292 associations.
Vendor sourcing (3)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.445C>T (p.R149W) alteration is located in exon 3 (coding exon 3) of the PRKCH gene. This alteration results from a C to T substitution at nucleotide po... | View ClinVar record SCV003526474.3 |
| Johns Hopkins University | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001430656.1 |
| Labcorp Holdings Inc. | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | No supporting text recorded; see the citation. | View ClinVar record SCV001030402.1 |
Trial-cited literature (7)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The Role of Adaptogens in Prophylaxis and Treatment of Viral Respiratory Infections. | Pharmaceuticals (Basel, Switzerland) | 2020 | 33 |
| Replicable and Coupled Changes in Innate and Adaptive Immune Gene Expression in Two Case-Control Studies of Blood Microarrays in Major Depressive Disorder. | Biological psychiatry | 2018 | 193 |
| Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. | Oncotarget | 2016 | 509 |
| Transcriptome profiling and pathway analysis of genes expressed differentially in participants with or without a positive response to topiramate treatment for methamphetamine addiction. | BMC medical genomics | 2014 | 18 |
| Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. | Molecular medicine (Cambridge, Mass.) | 2010 | 108 |
Showing 5 of 7 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G55A | 1 | 2015 | PMID 25741868 |
| p.V374I | 1 | 2010 | PMID 20852671 |
Organizations publishing (15)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Hospital | 1 | 2001 |
| Dana-Farber Cancer Institute | Other | 1 | 2016 |
| Duke University | Academic | 1 | 2010 |
| Harvard Medical School | Academic | 1 | 2016 |
| Mass General Brigham | Hospital | 1 | 2016 |
Showing 5 of 15 organizations.
Where PRKCH appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- respiratory or thoracic disease
286 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, trial mentions, human sample screening reference, and literature-extracted relations.